Skip to content

Prospective observational study on the changes of population reactive antibodies after allogeneic vascular replacement

Clinical application of standardized surgical treatment of pancreatic cancer with portal vein involvement

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061718
Enrollment
Unknown
Registered
2022-07-01
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Carcinoma

Interventions

Vascular replacement group:Allograft replacement of portal vein system invaded by pancreatic cancer

Sponsors

Beijing Chaoyang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old, regardless of gender; 2. Preoperative imaging examination showed that important abdominal veins were invaded or damaged; 3. There was no invasion of celiac trunk, superior mesenteric artery and other important arteries before operation; 4. There was no distant organ metastasis such as liver and lung; 5. There were no contraindications such as cardiopulmonary surgery; 6. PS score 0-2 copies; 7. The estimated survival time before operation was more than 6 months; ( 8. The patients and their families agreed to the study protocol and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Radical operation was abandoned because of distant metastasis during operation; 2. Radical operation was abandoned due to the invasion of important arteries such as celiac trunk and superior mesenteric artery; 3. Intraoperative evaluation does not require the use of allogeneic vein reconstruction; 4. Patients and their families refused the study protocol and asked to withdraw.

Design outcomes

Primary

MeasureTime frame
Group reactive antibody screening;Patency rate;overall survival time;disease free survival time;

Countries

China

Contacts

Public ContactQiang He
heqiang349@163.com+86 10 85231504

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026